|
8. An improved immunoadsorbent for isolation and purification of viii:C from viii:C/viii:RP comprising a monoclonal antibody specific to viii:RP bound to solid particles.
15. In a method for purifying factor viii procoagulant activity protein from plasma or concentrate, the improvement comprising the step of passing said plasma or concentrate through a chromatographic type column having adsorbent to which is bound monoclonal antibodies which is specific to viii:RP and eluting the viii-C therefrom.
1. An improved method of preparing factor viii procoagulant activity protein comprising the steps of
(a) adsorbing a viii:C/viii:RP complex from a plasma or commercial concentrate source onto particles bound to a monoclonal antibody specific to viii:RP, (b) eluting the viii:C, (c) adsorbing the viii:C obtained in step (b) in another adsorption to concentrate and further purify same, (d) eluting the adsorbed viii:C, and (e) recovering highly purified and concentrated viii:C.
2. A method according to
4. The method according to
6. The method according to
7. The method according to
12. The improved immunoadsorbent of
13. Highly purified and concentrated human or porcine viii:C prepared in accordance with the method of
14. Highly purified and concentrated human or porcine viii:C prepared in accordance with the method of
16. The method according to
17. A viii:C of
being substantially free of viii:RP. 25. A human viii:C preparation of claim 24, wherein the viii:C concentration is at least 160,000 fold purified relative to viii:C in plasma. 26. A human viii:C preparation of claim 24, wherein the ratio of viii:C to viii:RP is greater than 100,000 times the ratio in plasma. 27. A human viii:C preparation of claim 24, wherein said viii:C is isolated from viii:C/viii:RP and 90-100 percent of the viii:RP has been removed. 28. A human viii:C preparation having a specific activity greater than 2240 units/mg. 29. A human viii:C preparation of claim 28 wherein the potency is in the range of 134 to 1172 units/ml. 30. An improved method of preparing factor viii procoagulant activity protein comprising the steps of (a) adsorbing a viii:C/viii:RP complex from a plasma or commercial concentrate source onto a substrate to which is bound a monoclonal antibody specific to viii:RP, (b) eluting the viii:C, (c) adsorbing the viii:C obtained in step (b) in another adsorption to concentrate and further purify same, (d) eluting the adsorbed viii:C, and (e) recovering highly purified and concentrated viii:C. A method according to claim 30, wherein said substrate is a resin. 32. A method according to claim 30, wherein said substrate is comprised of particles. 33. An improved immunoadsorbent for isolation and purification of viii:C from viii:C/viii:RP comprising a monoclonal antibody specific to viii:RP bound to a substrate. 34. Highly purified and concentrated human or porcine viii:C prepared in accordance with the method of claim 30. 35. In a method for purifying factor viii procoagulant activity protein from plasma or concentrate, the improvement comprising the step of passing said plasma or concentrate over a substrate to which is bound monoclonal antibodies which are specific to viii:RP and eluting the viii:C therefrom. 36. The method according to claim 35, wherein said substrate is agarose and said elutant is a saline solution. |
Zimmerman, Theodore S., Fulcher, Carol A.
Patent | Priority | Assignee | Title |
10064946, | May 14 2010 | Amgen Inc. | High concentration antibody formulations |
10233237, | Nov 21 2012 | Amgen Inc | Heterodimeric immunoglobulins |
10273293, | Sep 17 2007 | Amgen Inc. | Method for inhibiting bone resorption |
10308704, | Nov 26 2008 | Amgen Inc. | Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof |
10407487, | Mar 06 2007 | Amgen Inc. | Variant activin receptor |
10538584, | Aug 04 2011 | Amgen Inc | Methods for treating bone gap defects |
10562964, | May 03 2005 | Amgen Inc. | Methods for isolating antibodies that bind sclerostin |
10799583, | Jul 05 2012 | UCB Pharma, S.A. | Treatment for bone diseases |
11040102, | May 14 2010 | Amgen Inc. | High concentration antibody formulations |
11091537, | Sep 17 2007 | Amgen Inc. | Method for inhibiting bone resorption |
11414482, | Nov 08 2016 | University of Miami | Anti-secretogranin III (SCG3) antibodies and uses thereof |
11466078, | Nov 21 2012 | Amgen Inc. | Heterodimeric immunoglobulins |
11466079, | Mar 30 2018 | Amgen Inc. | C-terminal antibody variants |
11541070, | Feb 01 2013 | Atara Biotherapeutics, Inc. | Administration of an anti-activin-A compound to a subject |
11576970, | Mar 10 2016 | UCB BIOPHARMA SRL | Pharmaceutical formulations |
11685770, | Nov 26 2008 | Amgen Inc. | Stabilized receptor polypeptides and uses thereof |
11702468, | Jun 16 2003 | UCB Pharma, S.A. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
11851483, | Dec 12 2014 | UCB PHARMA, S A | Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen |
11858983, | Mar 30 2018 | Amgen Inc. | C-terminal anti-sclerostin antibody variants |
11896667, | Jul 05 2012 | UCB Pharma S.A. | Treatment for bone diseases |
11939372, | May 03 2005 | Amgen Inc. | Binding agents |
12178873, | May 14 2010 | Amgen Inc. | High concentration antibody formulations |
4831118, | Aug 07 1987 | FLEET CAPITAL CORPORATION, AS AGENT | Flouroplastic immunoaffinity columns for purification of blood proteins |
4877608, | Nov 09 1987 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
4925574, | Jun 26 1985 | HER MAJESTY THE QUEEN AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE OF HER MAJESTY S CANADIAN GOVERNMENT | Purification of hemoglobin and modified hemoglobin by affinity chromatography |
5006642, | Jun 29 1987 | ARMOUR PHARMACEUTICAL PRODUCTS INC | Purification of von Willebrand Factor by affinity chromatography |
5043428, | Aug 31 1984 | CSL Behring GmbH | Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production |
5198349, | Jan 03 1986 | Genetics Institute, LLC | Method for producing factor VIII:C and analogs |
5200510, | Jun 16 1987 | ZymoGenetics, Inc. | Method for purifying factor VIII:C, von Willebrand factor and complexes thereof |
5288853, | Apr 30 1992 | GRIFOLS INC | Factor viii purification process |
5362854, | Mar 31 1983 | Scripps Clinic & Research Foundation | Factor VIII coagulant polypeptides: method of making |
5364771, | Apr 07 1992 | Emory University | Hybrid human/porcine factor VIII |
5470954, | Mar 31 1987 | Baxter International Inc. | Ultrapurification process for factor VIII |
5605884, | Oct 29 1987 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
5618788, | Apr 20 1984 | Genentech, Inc. | Preparation of functional human factor VIII and pharmaceutical treatment therewith |
5618789, | Apr 20 1984 | Genentech, Inc. | Functional human factor VIII |
5633150, | Apr 20 1984 | Genentech, Inc | Preparation of functional human factor VIII |
5654147, | Apr 20 1984 | Genentech, Inc | Method of hybridization using oligonucleotide probes |
5659017, | Nov 07 1995 | GRIFOLS INC | Anion exchange process for the purification of Factor VIII |
5663060, | Apr 07 1992 | Emory University | Hybrid human/animal factor VIII |
5668108, | Apr 20 1984 | Genentech, Inc. | Preparation of functional human factor VIII and pharmaceutical treatment therewith |
5683905, | Apr 20 1984 | Genentech, Inc. | Vectors and cell lines capable of correctly splicing exon regions |
5744446, | Apr 07 1992 | Emory University | Hybrid human/animal factor VIII |
5747337, | Mar 31 1983 | The Scripps Research Institute | Factor VIII coagulant polypeptides and monoclonal antibodies to them |
5783671, | Jan 12 1984 | Chiron Corporation; Novo Nordisk A/S | Method and composition for preparation of factor VIIIC |
5888974, | Apr 07 1992 | Emory University | Hybrid human/animal factor VIII |
5994310, | Sep 03 1998 | Bayer Corporation | Peptide ligands for affinity purification of human Factor VIII |
6248555, | Aug 31 1995 | General Hospital Corporation, The | Genetic alterations related to familial alzheimer's disease |
6864235, | Apr 01 1999 | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans | |
6911429, | Apr 01 1999 | TRANSITION THERAPEUTICS INC | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
7063850, | Dec 22 1998 | University of Tennessee Research Foundation | Protective antigen of group A Streptococci |
7087420, | Jul 11 1997 | Cambia | Microbial β-glucuronidase genes, gene products and uses thereof |
7141719, | Sep 09 1997 | Cambia | Microbial β-Glucuronidase genes, gene production and uses thereof |
7270827, | Oct 26 2001 | University of Tennessee Research Foundation | Multivalent streptococcal vaccine compositions and methods for use |
7572899, | Nov 27 1998 | UCB S A ; UCB PHARMA S A | Compositions and methods for increasing bone mineralization |
7592429, | May 03 2005 | Amgen Inc | Sclerostin-binding antibody |
7659375, | Aug 21 1998 | Immunex Corporation | Human IL-1 epsilon DNA and polypeptides |
7700277, | Jul 26 2003 | AstraZeneca AB | Use of polymorphisms in human OATP-C associated with an effect on statin pharmacokinetics in humans in statin therapy |
7758858, | Nov 27 1998 | UCB S A ; UCB PHARMA S A | Antibodies associated with alterations in bone density |
7799523, | Apr 03 2002 | Erasmus University Rotterdam | Association of polymorphisms in the SOST gene region with bone mineral density |
7868134, | Jun 16 2003 | UCB PHARMA S A | Immunogenic peptides derived from sclerostin |
7872106, | May 03 2005 | UCB PHARMA S A | Sclerostin-binding antibodies |
7977312, | Nov 27 1998 | UCB S A ; UCB PHARMA S A | Compositions and methods for increasing bone mineralization |
7985834, | Jun 16 2003 | UCB PHARMA S A | Compositions and methods for increasing bone mineralization |
7994299, | Nov 27 1998 | UCB S A ; UCB PHARMA S A | Compositions and methods for increasing bone mineralization |
8003108, | May 03 2005 | UCB SA | Sclerostin epitopes |
8017120, | Sep 17 2007 | Amgen Inc | Method for inhibiting bone resorption |
8329176, | Sep 17 2007 | Amgen Inc. | Method for inhibiting bone resorption |
8383801, | May 03 2005 | Amgen Inc. | Polynucleotide encoding a sclerostin-binding antibody |
8410043, | Nov 26 2008 | Amgen Inc | Stabilized activin IIB receptor polypeptides and uses thereof |
8440193, | Sep 17 2007 | Amgen Inc. | Method for inhibiting bone resorption |
8563271, | Jun 16 2003 | UCB PHARMA S A | Antibodies specific for sclerostin and methods for increasing bone mineralization |
8637643, | May 03 2005 | UCB PHARMA S A | Sclerostin binding antibody |
8715663, | May 03 2005 | Amgen Inc. | Epitopes |
8986685, | Nov 27 1998 | UCB S A ; UCB PHARMA S A | Compositions and methods for increasing bone mineralization |
8992911, | Jun 16 2003 | UCB PHARMA S A | Antibodies specific for sclerostin and methods for increasing bone mineralization |
8999917, | Mar 06 2007 | Amgen Inc. | Variant activin receptor polypeptides and uses thereof |
9011856, | Jun 16 2003 | UCB PHARMA S A | Antibodies specific for sclerostin and methods for increasing bone mineralization |
9089553, | Sep 17 2007 | Amgen Inc. | Method for inhibiting bone resorption |
9133272, | Mar 01 2011 | Amgen Inc | Bispecific binding agents |
9145457, | Mar 25 2011 | Amgen Inc | Sclerostin antibody crystals and formulations thereof |
9296812, | May 03 2005 | Amgen Inc. | Sclerostin binding antibodies |
9352043, | May 14 2010 | Amgen Inc | High concentration antibody formulations |
9353174, | May 03 2005 | Amgen Inc. | Epitopes |
9382309, | Mar 06 2007 | Amgen Inc. | Variant activin IIB receptor |
9447165, | Mar 06 2007 | Amgen Inc | Variant activin IIB receptor |
9610327, | Dec 19 2011 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
9617333, | Mar 25 2011 | Amgen Inc. | Sclerostin antibody crystals and formulations thereof |
9657090, | Dec 28 2011 | Amgen Inc | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
9657095, | Jun 16 2003 | UCB Pharma S.A. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
9791462, | Nov 27 1998 | UCB Pharma, S.A. | Compositions and methods for increasing bone mineralization |
9809638, | Mar 06 2007 | Amgen Inc. | Variant activin receptor |
9822173, | Nov 21 2012 | Amgen Inc | Heterodimeric immunoglobulins |
9913900, | Dec 28 2011 | Amgen Inc.; The Regents of the University of Michigan | Method of treating alvelor bone loss through the use of anti-sclerostin antibodies |
9920114, | Mar 25 2011 | Amgen Inc. | Antibody formulations |
9925260, | Jul 05 2012 | UCB PHARMA S A | Treatment for bone diseases |
Patent | Priority | Assignee | Title |
3631018, | |||
3652530, | |||
3682881, | |||
3973002, | Apr 12 1974 | E. R. Squibb & Sons, Inc. | Antihemophilic factor |
4069216, | Jun 16 1975 | Edward Shanbrom, Inc. | Simplified methods for preparation of very high purity Factor VIII concentrate |
4137223, | Apr 11 1975 | Edward Shanbrom, Inc. | Method of preserving blood plasma II |
4188318, | Jun 16 1975 | INSTITUT MERIEUX, A CORP OF FRANCE | Simplified method for preparation of high yield, high purity Factor VIII concentrate |
4203891, | Dec 19 1977 | CANADIAN RED CROSS SOCIETY, THE | Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin |
4272521, | Jul 16 1979 | Cutter Laboratories, Inc. | Purified immune serum globulin |
4296027, | Aug 31 1977 | The Regents of the University of Minnesota | Pure intravenous human and animal gamma globulins |
4302445, | Jan 18 1980 | MERIEUX S A | Method for concentrating and purifying antihemophilic factor or factor VIII |
4348315, | Dec 20 1979 | Process in purification and concentration of the factor VIII-complex | |
4361510, | May 27 1980 | Cutter Laboratories, Inc. | Blood coagulation promoting product |
4361550, | Dec 04 1979 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same |
4361647, | May 22 1980 | Palo Alto Medical Research Foundation | Sandwich immunoassay and compositions for use therein |
4362867, | Dec 10 1980 | RESEARCH CORPORATION TECHNOLOGIES, INC , A NONPROFIT CORP OF DE; Medical University of South Carolina | Recombinant cDNA construction method and hybrid nucleotides useful in cloning |
4364861, | May 27 1980 | IMMUNO AKTIENGESELLSCHAFT FUR CHEMISCH-MEDIZINISCHE PRODUKTE IMMUNO , A CORP OF AUSTRIA | Blood-coagulation-promoting products and methods of preparing them |
4364932, | Sep 18 1979 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same |
4364933, | Dec 04 1979 | Ortho Pharmaceutical Corporation | Monoclonal antibody to a human thymocyte antigen and methods of preparing same |
4364934, | Dec 04 1979 | Ortho Pharmaceutical Corporation | Monoclonal antibody to a human early thymocyte antigen and methods for preparing same |
4364935, | Dec 04 1979 | Ortho Pharmaceutical Corporation | Monoclonal antibody to a human prothymocyte antigen and methods of preparing same |
4364936, | Jan 08 1980 | Ortho Pharmaceutical Corporation | Monoclonal antibody to a human monocyte antigen and methods of preparing same |
4364937, | Jan 08 1980 | Ortho Pharmaceutical Corporation | Monoclonal antibody to a human T cell antigen and methods of preparing same |
4373932, | Jan 11 1980 | Akzona Incorporated | Application of water-dispersible hydrophobic dyes or pigments as labels in immunoassays |
4376110, | Aug 04 1980 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
4381292, | Nov 14 1980 | BOARD OF TRUSTEES OF LELAND STANFORD JR UNIVERSITY, STANFORD UNIVERISTY, A CORP OF CA | Anti-human T-lymphocyte monoclonal antibody |
4381295, | Apr 26 1979 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human helper T cells and methods of preparing same |
EP38642, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Dec 21 1983 | Scripps Clinic and Research Foundation | (assignment on the face of the patent) | ||||
Oct 30 1991 | Scripps Clinic and Research Foundation | SCRIPPS RESEARCH INSTITUTE, THE, A CORP OF CA | ASSIGNMENT OF ASSIGNORS INTEREST | 006167 | 0046 |
Date | Maintenance Fee Events |
Apr 21 1986 | M170: Payment of Maintenance Fee, 4th Year, PL 96-517. |
May 01 1990 | M171: Payment of Maintenance Fee, 8th Year, PL 96-517. |
May 11 1990 | ASPN: Payor Number Assigned. |
May 02 1994 | M185: Payment of Maintenance Fee, 12th Year, Large Entity. |
May 16 1994 | ASPN: Payor Number Assigned. |
May 16 1994 | RMPN: Payer Number De-assigned. |
Date | Maintenance Schedule |
Oct 22 1988 | 4 years fee payment window open |
Apr 22 1989 | 6 months grace period start (w surcharge) |
Oct 22 1989 | patent expiry (for year 4) |
Oct 22 1991 | 2 years to revive unintentionally abandoned end. (for year 4) |
Oct 22 1992 | 8 years fee payment window open |
Apr 22 1993 | 6 months grace period start (w surcharge) |
Oct 22 1993 | patent expiry (for year 8) |
Oct 22 1995 | 2 years to revive unintentionally abandoned end. (for year 8) |
Oct 22 1996 | 12 years fee payment window open |
Apr 22 1997 | 6 months grace period start (w surcharge) |
Oct 22 1997 | patent expiry (for year 12) |
Oct 22 1999 | 2 years to revive unintentionally abandoned end. (for year 12) |